166 related articles for article (PubMed ID: 20974687)
1. BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP.
Salles D; Mencalha AL; Ireno IC; Wiesmüller L; Abdelhay E
Carcinogenesis; 2011 Jan; 32(1):27-34. PubMed ID: 20974687
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL stimulates WRN to promote survival and genomic instability.
Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
[TBL] [Abstract][Full Text] [Related]
3. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Cramer K; Nieborowska-Skorska M; Koptyra M; Slupianek A; Penserga ET; Eaves CJ; Aulitzky W; Skorski T
Cancer Res; 2008 Sep; 68(17):6884-8. PubMed ID: 18757400
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
7. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle.
Yun MH; Hiom K
Nature; 2009 May; 459(7245):460-3. PubMed ID: 19357644
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.
Fernandes MS; Reddy MM; Gonneville JR; DeRoo SC; Podar K; Griffin JD; Weinstock DM; Sattler M
Blood; 2009 Aug; 114(9):1813-9. PubMed ID: 19571320
[TBL] [Abstract][Full Text] [Related]
9. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Spencer A; Granter N
Exp Hematol; 1999 Sep; 27(9):1397-401. PubMed ID: 10480430
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.
Poplawski T; Blasiak J
Mol Biol Rep; 2010 Jun; 37(5):2309-15. PubMed ID: 19697154
[TBL] [Abstract][Full Text] [Related]
11. DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.
Pawlowska E; Blasiak J
Int J Mol Sci; 2015 Nov; 16(11):27535-49. PubMed ID: 26593906
[TBL] [Abstract][Full Text] [Related]
12. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
13. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
14. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and CtIP Are Both Required to Recruit Dna2 at Double-Strand Breaks in Homologous Recombination.
Hoa NN; Kobayashi J; Omura M; Hirakawa M; Yang SH; Komatsu K; Paull TT; Takeda S; Sasanuma H
PLoS One; 2015; 10(4):e0124495. PubMed ID: 25909997
[TBL] [Abstract][Full Text] [Related]
16. Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways.
Zhu Y; Dai H; Wang Y; Liang Y; Feng W; Yuan Y
DNA Cell Biol; 2021 Aug; 40(8):1101-1111. PubMed ID: 34156283
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Sallmyr A; Tomkinson AE; Rassool FV
Blood; 2008 Aug; 112(4):1413-23. PubMed ID: 18524993
[TBL] [Abstract][Full Text] [Related]
18. DNA end resection requires constitutive sumoylation of CtIP by CBX4.
Soria-Bretones I; Cepeda-García C; Checa-Rodriguez C; Heyer V; Reina-San-Martin B; Soutoglou E; Huertas P
Nat Commun; 2017 Jul; 8(1):113. PubMed ID: 28740167
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
20. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
